Skip to main content

Research Repository

Advanced Search

SGLT?2 Inhibitor Renal Outcome Modification in Type?2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk

Schernthaner, Guntram; Groop, Per-Henrik; Kalra, Philip A.; Ronco, Claudio; Taal, Maarten W.

SGLT?2 Inhibitor Renal Outcome Modification in Type?2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk Thumbnail


Authors

Guntram Schernthaner

Per-Henrik Groop

Philip A. Kalra

Claudio Ronco



Abstract

Data from three completed cardiovascular outcome trials (CVOTs), EMPA?REG OUTCOME, CANVAS Program and DECLARE?TIMI 58, add to the evidence supporting the potential renoprotective effects of sodium?glucose linked transporter?2 (SGLT2) inhibitors in patients with type?2 diabetes (T2D). Despite recommendations in recent guidelines, it is difficult to support a view that definitive evidence for renoprotection exists from these SGLT2 inhibitor CVOT results. To date, the only dedicated trial to report definitive data on the renal impact of SGLT2 inhibition is CREDENCE. Notably, the total number of patient relevant renal endpoint events (dialysis, transplant or renal death) observed in CREDENCE was significantly higher than the total for all three CVOTs collectively (183 events/4,401 patients vs. 69 events/34,322 patients, respectively), which demonstrates the increased statistical power of CREDENCE for these renal endpoints. Treatment with canagliflozin was associated with a 30% relative risk reduction (RRR) in the primary composite endpoint of end?stage kidney disease, doubling of serum creatinine, or death from renal or cardiovascular causes and a 34% RRR for the renal?specific elements of this primary endpoint (P

Citation

Schernthaner, G., Groop, P., Kalra, P. A., Ronco, C., & Taal, M. W. (2020). SGLT?2 Inhibitor Renal Outcome Modification in Type?2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk. Diabetes, Obesity and Metabolism, 22(7), 1024-1034. https://doi.org/10.1111/dom.13994

Journal Article Type Article
Acceptance Date Feb 4, 2020
Online Publication Date Feb 9, 2020
Publication Date 2020-07
Deposit Date Feb 6, 2020
Publicly Available Date Mar 28, 2024
Journal Diabetes, Obesity and Metabolism
Print ISSN 1462-8902
Electronic ISSN 1463-1326
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 22
Issue 7
Pages 1024-1034
DOI https://doi.org/10.1111/dom.13994
Keywords Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology
Public URL https://nottingham-repository.worktribe.com/output/3909298
Publisher URL https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13994
Additional Information Received: 2019-12-05; Accepted: 2020-02-04; Published: 2020-02-09